TY - JOUR
T1 - Community-acquired pneumonia in the United Kingdom
T2 - a call to action
AU - Chalmers, James
AU - Campling, James
AU - Ellsbury, Gillian
AU - Hawkey, Peter M.
AU - Madhava, Harish
AU - Slack, Mary
N1 - Dr. James Chalmers, Prof. Peter Hawkey and Prof. Mary Slack received honoraria from Pfizer in connection with the development of this manuscript. Pfizer also provided funding for the following: Hospital Episode Statistics (HES) data processing and analysis by Harvey Walsh Ltd. under an NHS digital re-use agreement, medical writing support by Richard Watt of Sudler Medical Communications, and journal publication charges.
PY - 2017/10/5
Y1 - 2017/10/5
N2 - Pneumococcal disease has a high burden in adults in the United Kingdom (UK); however, the total burden is underestimated, principally because most cases of community-acquired pneumonia (CAP) are non-invasive. Research into pneumonia receives poor funding relative to its disease burden (global mortality, disability-adjusted life years, and years lived with disability), ranking just 20 out of 25 for investment in infectious diseases in the UK. The current accuracy of data for establishing incidence rates is questionable, and it is a reflection of the paucity of research that much of the background information available derives from nearly 30 years ago. Given the relationship between CAP and mortality (pneumonia accounts for 29,000 deaths per annum in the UK, and 5-15% of patients hospitalised with CAP die within 30 days of admission), and the increasing threat of antimicrobial resistance associated with inappropriate antibiotic prescribing, such neglect of a highly prevalent problem is concerning. In this Call to Action, we explore the poorly understood burden of CAP in the UK, discuss the importance of an accurate diagnosis and appropriate treatment, and suggest how national collaboration could improve the management of an often life-threatening, yet potentially preventable disease.
AB - Pneumococcal disease has a high burden in adults in the United Kingdom (UK); however, the total burden is underestimated, principally because most cases of community-acquired pneumonia (CAP) are non-invasive. Research into pneumonia receives poor funding relative to its disease burden (global mortality, disability-adjusted life years, and years lived with disability), ranking just 20 out of 25 for investment in infectious diseases in the UK. The current accuracy of data for establishing incidence rates is questionable, and it is a reflection of the paucity of research that much of the background information available derives from nearly 30 years ago. Given the relationship between CAP and mortality (pneumonia accounts for 29,000 deaths per annum in the UK, and 5-15% of patients hospitalised with CAP die within 30 days of admission), and the increasing threat of antimicrobial resistance associated with inappropriate antibiotic prescribing, such neglect of a highly prevalent problem is concerning. In this Call to Action, we explore the poorly understood burden of CAP in the UK, discuss the importance of an accurate diagnosis and appropriate treatment, and suggest how national collaboration could improve the management of an often life-threatening, yet potentially preventable disease.
KW - Editorial
KW - Antimicrobial resistance
KW - Clostridium Difficile
KW - Community-acquired pneumonia
KW - Immunization
KW - Pneumococcal disease
KW - Pneumonia burden
KW - Pneumonia diagnostics
KW - Pneumonia epidemiology
KW - Streptococcus Pneumoniae
U2 - 10.1186/s41479-017-0039-9
DO - 10.1186/s41479-017-0039-9
M3 - Comment/debate
C2 - 29043150
SN - 2200-6133
VL - 9
JO - Pneumonia
JF - Pneumonia
M1 - 15
ER -